Molecular Diagnostics

British Journal of Cancer (2007) 97, 412–419. doi:10.1038/sj.bjc.6603867 www.bjcancer.com
Published online 26 June 2007

Foetal haemoglobin-blood cells (F-cells) as a feature of embryonic tumours (blastomas)

M Wolk1,2, J E Martin1 and M Nowicki2

  1. 1Department of Histopathology, Royal London Hospital, Centre for pathology, Institute of Cell and Molecular Sciences, Queen Mary School of Medicine and Dentistry, Pathology and Pharmacy Building, The Royal London Hospital, 80 Newark Street, Whitechapel, London E1 2ES, UK
  2. 2Department of Histology and Embryology, Poznan University of Medical Sciences, Swiecickiego 6, Poznan 60-781, Poland

Correspondence: Dr M Wolk, Tarshish st 14, PO BOX 4710, Ma'ale-Adumim 98451, Israel. E-mail: wolk1@bezeqint.net

Received 29 January 2007; Revised 3 May 2007; Accepted 5 June 2007; Published online 26 June 2007.

Top

Abstract

Tumour markers are important in the diagnosis and monitoring of many tumours. This study tested the hypothesis that an oncofoetal protein, foetal haemoglobin (HbF) is a potential tumour marker in embryonic tumours, useful for management. An immunohistochemical investigation of HbF blood cell (Fc) distribution was carried out in tumours and in bone marrow samples from 83 children and 13 adults with various embryonic tumours (blastomas), and in bone marrow samples of 24 leukaemia patients. In the three, main blastoma types, nephroblastoma (Wilms' tumour), neuroblastoma and retinoblastoma, where all the patients, except two, were children, around 80% of the tumour samples had Fc within proliferating blood vessels and spaces between tumour cells. In parallel, clusters of Fc, mostly F-erythroblasts (Feb), were distributed in the bone marrow of some of those patients and in the bone marrow of 79% of the leukaemia patients. Foetal haemoglobin, as well as being a potential prognostic cancer marker, is a potential indicator of DNA hypomethylation implicated in the development of these tumours, as well as in others previously noted for the presence of HbF.

Keywords:

foetal haemoglobin, tumour marker, embryonic tumours, DNA hypomethylation, childhood cancer

Elevated concentrations of foetal haemoglobin (HbF) are common in the predominant kinds of solid tumours as well as in haematological malignancies (Wolk et al, 1991, 1999). In preliminary follow-up studies conducted on childhood leukaemia (Rautonen and Siimes, 1990), in myelodysplastic syndrome (Reinhardt et al, 1998) and in non-Hodgkin's lymphoma (Wolk and Newlands, 2004), HbF has been evaluated as a valid prognostic parameter, which should be considered in the management of the disease. There is evidence that HbF inducing growth factors are raised in cancer patients, including stem cell growth factor (CSF) and interleukin-3 in the serum of colorectal cancer patients (Mroczko et al, 2003), and a growth factor found in the bone marrow of patients with myelodysplastic syndrome (Choi et al, 2002). However, the mechanisms for renewal of globin italic gamma-chain gene expression in cancer patients are yet not clear. Foetal haemoglobin in most cases is not a product of the tumour cells. Foetal haemoglobin expression by the blood cells surrounding the tumour appears to be induced under the conditions of malignancy. Defining these conditions might contribute to the understanding of carcinogenesis at its basic levels. In this respect, we note that DNA hypomethylation (DNhpom) at CpG dinucleotides (cytosine nucleotide found adjacent to guanine nucleotide) is an example of an epigenetic process implicated in the promotion of carcinogenesis (Ehrlich, 2005), as well as in the activation of globin italic gamma-chain gene expression (Atweh et al, 2003; Lavelle, 2004). For example, DNhpom was proved experimentally to promote hepatocellular carcinogenesis (Yamada et al, 2005) and T-cell lymphoma (Gaudet et al, 2003), and to correlate with recurrence in hepatocellular carcinoma (Itano et al, 2002). In parallel, a DNA hypomethylating cytidine analogue drug given to lung cancer patients (Carr et al, 1987) and to patients with sickle cell disease (Saunthararajah et al, 2004) increased their HbF concentrations. In the sickle cell patients, HbF rose to 22% (normal level is<1%). Hence, DNhpom agents might promote neoplasia in prospective tumour cells simultaneously with reactivation of HbF gene expression in erythrocytes precursors, residing inside the tumour tissues or in haematopoietic tissues of the same organism. This hypothesis is not impaired by the evidence for inactivation of tumour suppressing genes by DNA hypermethylation, since hypermethylation is specific for unique genomic sites while at the same time global DNA is hypomethylated (Ehrlich et al, 2002; Brothman et al, 2005; Ehrlich, 2005). By that ambiguity, the use of DNA demethylating agents as therapeutic anticancer regiment might contribute to carcinogenesis (Ehrlich, 2005). By establishing the association between carcinogenesis and HbF via DNhpom, detection of HbF might contribute to therapeutic strategies, and to the alerting of hypomethylating agents in the environment, suspected as carcinogenic hazards. The first indication for a possible link between DNhpom in tumour tissue (in the tissues of colorectal adenocarcinoma) and DNhpom of the italic gamma-globin gene came by demonstrating hybridization between the two sources of DNA (Feinberg and Vogelstein, 1983). Since then, DNhpom has been found in a large variety of tumour tissues, including leukaemia (Yoshida et al, 2004), prostate (Brothman et al, 2005), breast (Van den Eyden et al, 2005), urinary bladder (Nakagawa et al, 2005) and others, most of them known for elevated HbF. Another group of solid tumours notable for DNhpom, is embryonic tumours (blastomas), which are most common in children.

The aim of this study was to investigate the presence of F-cells in blastoma-related tumours by the use of immunohistochemistry. In this way, conditions inducing HbF expression can be related locally to the tumour tissue, rather than to the whole organism, as in our study of colorectal tumours, where we detected local development of F-cells (Wolk et al, 2006).

Our study included Wilms' tumour (nephroblastoma), neuroblastoma, retinoblastoma, childhood leukaemia, rhabdomyosarcoma and others, all of which originate from primordial embryonic cells, including the embryonic neural crest as the presumed source of neuroblastoma, Ewing's sarcoma, medulloblastoma and rhabdomyosarcoma. All have similar morphology, with uniform, primitive embryonic, blastoma cells. Some of them are reported to share the same oncogenes, as WT1 in Wilms' tumour (Maiti et al, 2000), in retinoblastoma (Wagner et al, 2002) and in acute myeloid leukaemia (King-Underwood et al, 1996), and RB1 in retinoblastoma (Sanchez et al, 2000), neuroblastoma (Markaki et al, 2001), childhood leukaemia (Markaki et al, 2001) and Ewing's sarcoma (Cope et al, 2001). We evaluated HbF as a cancer marker in those diseases by examining the histological distribution of F-cells in the tumours and bone marrow of those patients, noting their concentrations and locations.

Top

Materials and methods

Participants

The study was conducted in two institutions: (1) Pathology Group, Institute of Cell and Molecular Sciences, The Royal London Hospital, England and (2) Department of Histology and Embryology, Poznan University of Medical Sciences, Poland. The programme of research including studies on archival and stored materials was approved by The East London and City Health Authority Research Ethics Committee and by the Poznan University of Medical Sciences, Department of Paediatric Oncology, Haematology and Transplantology, Ethics Committee.

Immunohistochemical staining

We used the peroxidase avidin–biotin method with an affinity purified anti-HbF (Wolk et al, 2004). All the reagents used, as well as the procedures of immunostaining confirmed by control staining, were as described in our previous work (Wolk et al, 2004). The intensity of staining was indicated by five grades from (+) to (+++++).

Top

Results

General

The study included examination of histological tumour and bone marrow specimens of the following diseases: nephroblastoma (n=24), leukaemia (n=24), retinoblastoma (n=18), neuroblastoma (n=17), rhabdomyosarcoma (n=14), medulloblastoma (n=11), Ewing's sarcoma (n=2), hepatoblastoma, neurofibroma and glioblastoma (n=1 for each). All these patients, except those with leukaemia and medulloblastoma, were predominantly children.

Foetal haemoglobin blood cells (Fc) comprised mature erythrocytes (Fer) and nucleated erythroblasts (Feb), which could sometimes be binucleated or in mitosis. Foetal haemoglobin blood cells were identified and were distributed in blood vessels or free in tumour tissues. In the blood vessels their concentrations were 0–100%. They could be distributed either randomly in the blood vessels, in most of the cases not exceeding 50% of the total blood cells (Figure 1A), or at 100% inside proliferating, closely aligned blood vessels (Figures 1B and 2A). In the following tables, cases classified as (1) 'low-percent Fer' (Fer+), were those with 0–30% Fc per one blood vessel, in which usually no more than 20% of the vessels contained Fc; (2)'high-percent Fer' (Fer++) were those with >30–100% Fc per one blood vessel, where usually 30–100% of the blood vessels contained Fc. Close to the proliferating blood vessels, there were packed free extravascular clusters of Fc, including many Feb, as in proliferation centres (Figure 2B). Usually Fc were also observed infiltrated among the tumour cells and congested in large areas of necrosis or haemorrhage (Figures 3A and B). In bone marrow, F-cells were observed in dense clusters of 3–50 cells distributed through the whole section (Figures 4 and 5).

Figure 1.
Figure 1 - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, please contact help@nature.com or the author

Nephroblastoma. (A) Large blood vessel in tumour tissue, containing 20% Fer. Calibration bar, 50 mum. (B) Tubular differentiating area with proliferating blood vessels full of Fc. Calibration bar, 50 mum. (C) Fc within glomeruloid body. Arrow indicates one Feb. Calibration bar, 25 mum.

Full figure and legend (304K)

Figure 2.
Figure 2 - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, please contact help@nature.com or the author

Retinoblastoma. (A) Proliferating blood vessels full of Fc. Thirty percent are (nucleated) Feb, two of which are indicated by arrow. Calibration bar, 50 mum. (B) A condensation of extravascular Fc (indicated by arrow) between the two blood vessels of Fc. Calibration bar, 50 mum.

Full figure and legend (355K)

Figure 3.
Figure 3 - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, please contact help@nature.com or the author

(A) Infiltrating Fc (orange immunostained) in neuroblastoma of the brain. To the left is a brain tissue free of Fc. Calibration bar, 50 mum. (B) Neurofibroma; an example of congested Fc in a necrotic area (bellow) and Fc infiltrated into tumour tissue (above). Calibration bar, 50 mum.

Full figure and legend (316K)

Figure 4.
Figure 4 - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, please contact help@nature.com or the author

Rhabdomyosarcoma. Bone marrow with a network forming clusters of Fer and Feb. Arrows indicate two Feb in mitosis. Calibration bar, 50 mum.

Full figure and legend (145K)

Figure 5.
Figure 5 - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, please contact help@nature.com or the author

Leukemia. (A) Bone marrow from hairy cell leukaemia with a large concentration of Feb and other dispersed. Feb and Fer. Calibration bar, 50 mum. (B) A cluster of Feb in a bone marrow from CML. Calibration bar, 25 mum.

Full figure and legend (266K)

The scarce cases treated by chemotherapy prior to our examination were noted in the tables of results.

Nephroblastoma

Table 1 summarizes the immunohistochemical distribution of Fc in 24 patients with tumours. Foetal haemoglobin blood cells were detected in 19 (79%) of these patients, all of them children aged 1–14 years (Table 1, numbers 1–9, 14–23). Control specimens included one normal kidney (Table 1, number 22), seven normal kidney tissues adjacent to a removed tumour (Table 1, numbers 10–13, 15, 16, 24) and three kidney tissues of patients with glomerulonephritis (Table 1, numbers 31–33). No Fc were observed in these controls, except one case (Table 1, number 10). Ten patients (Table 1, numbers 1–10) were followed up until the present time. However, no correlation could be found between the last clinical stage reported and the Fc distribution. All the tumours were of three-phase nephroblastoma, including all the three cellular components, namely: blastoma cells, mesenchyme and epithelial cells forming tubular elements. Foetal haemoglobin blood was found in each of these components, including tubular structures (Table 1, numbers 9, 10, 23) and glomeroid bodies (Table 1, number 7, 9; Figure 1C), as well as in the blood vessels (Table 1, numbers 1–8, 10, 15, 16, 17, 19, 20, 21; Figure 1A) Congested Fc were very common in large necrotic and haemorrhagic areas, or between tumour cells. Evidence was also found for proliferating blood vessels full of Fc (Table 1, numbers 2, 3, 8; Figure 1B).


Neuroblastoma

The results are summarized in Table 2. Tumour specimens were examined in 16 children, 2/12–14 years old and one adult. Twelve of them (75%) were Fc positive. Foetal haemoglobin blood cells, mainly Fer, were infiltrated among the tumour cells (as in Figures 3A and B) and randomly distributed inside blood vessels. No F-cells were found in ganglioneuroma (Table 2, number 5) or in brain tissue adjacent to the tumour tissue (Table 2, number 6; Figure 3A). No correlation could be found between the clinical condition and the distribution of Fc. In the bone marrow with metastases, high concentrations of Feb were observed in one patient (Table 2, number 14), while three other bone marrow samples were negative.


Retinoblastoma

The results are summarized in Table 3. Here again all patients were very young infants, most of them 3 years and younger. Eleven (78.6%) of the 14 tumour specimens were Fc positive. Non-metastatic bone marrow specimens from three out of four other patients were strongly positive for Fc, mostly Feb. The expression of foetal haemoglobin and the percentages of Feb were very prominent, exceeding all other tumour types examined here.


Some of the Feb were binucleated or in mitosis. We noted here the high rate of proliferating Fc in regenerating blood vessels and in free cell clusters (Table 3, numbers 1–4; Figures 2A and B)

Rhabdomyosarcoma

The results are summarized in Table 4. Eight (89%) of the nine tumour specimens were Fc positive. Tumour specimens were from seven children, 1–8 years old, and two adults. In tumour blood vessels, the F-cells were randomly distributed. Free Fc were distributed in tumour tissues as in the groups above. In bone marrow specimens from two of five patients, there were clusters of Fc, and high-rate Feb mitosis was noted in one of them (Figure 4).


Medulloblastoma

All specimens were from tumour in the cerebellum. As described in Table 5, five patients were children 5–15 years old and six other were young adults. Six of the 11 patients were Fc positive, with the characteristic distribution as above.


Leukaemia

A list of Fc positive and negative cases is shown in Table 6. Bone marrow specimens were examined from 24 patients; 19 (79%) of them were Fc positive. Seven patients were boys and girls aged 2–14 years. The remaining 17 adult patients were aged between 31 and 83 years. Our initial aim was to examine childhood leukaemia because it is considered as leukoblastoma (van den Berg, 2002). However, our results indicated that the incidence and magnitude of Fc distribution were the same for children and adults. There was also no difference with regards to the type of leukaemia. Foetal haemoglobin blood cells were distributed through the whole sections of the bone marrow as cluster of 3 to 50 cells, most of them Feb. All of them were strongly stained (+++++), as shown in Figures 5A and B.


Ewing's sarcoma
 

One tumour specimen, from the temporal bone of a 60-year-old man, had Fc distributed at 10–50% in part of the blood vessels and in necrotic areas. About 1/4 of these Fc were Feb. Another sacral tumour from a 2-year-old boy had a few fine blood vessels with 100% Fer.

Neurofibroma
 

In a tumour specimen from a cyst in the leg of 1-year-old boy, we observed Fc cells infiltrating among tumour cells and in adjacent necrotic areas, where some were Feb, as shown in Figure 3B.

Glioblastoma
 

Tumour specimen from the brain of a 52-year-old woman consisted of blastoma-like cells infiltrated by Fer. The adjacent brain tissue was free of Fc.

Hepatoblastoma
 

In a bone marrow specimen from a 2-year-old girl, we observed Fc, most of them Feb, distributed as foci and as single cells.

Top

Discussion

As described in the results, F-cells (Fc) were distributed in various patterns inside the embryonic tumour tissues. Foetal haemoglobin blood cells probably originate in the bone marrow and, delivered by circulation, were found randomly at 0–50% in the main blood vessels (Figure 1A). However, Fc including Feb comprised up to 100% of the contents of proliferating blood vessels and as packed free clusters (Figures 2A and B) could have originated in the tumour tissue. It seems therefore that there are two sources of Fc. One is in the bone marrow leading to elevated whole-blood HbF concentration, and the other is in the tumour tissue leading to elevated plasma HbF concentration. A support for this assumption is found in our previous works showing that plasma HbF and whole-blood HbF are two independent indicators in many kinds of cancer (Wolk et al, 1999). One of these cancers was non-Hodgkin's lymphoma, in the patients of which we have immunohistochemically detected Fc in lymph nodes and in bone marrow (Wolk et al, 2004), which respectively might have been the sources for (1) plasma HbF and (2) whole-blood HbF. We have found similar reciprocation (same references) in teratoma. However, these assumed correlations between the immunohistochemical and the serological findings have yet to be confirmed by concomitantly performing both essays. In our four main tumour groups comprising nephroblastoma, neuroblastoma, retinoblastoma and rhabdomyosarcoma, within the 60 cases of childhood embryonic tumours, we found prominent HbF expression in up to 80% of patients. This is the highest percentage of HbF ever detected immunohistochemically in cancer, which makes it an important feature of childhood embryonic tumour. Foetal haemoglobin measurements should therefore be considered in the management of those tumours, as the concentrations might change with regression or progression of the tumours. Foetal haemoglobin blood cells, most of them being Feb, were detected predominantly in the bone marrow of patients with leukaemia, but also in neuroblastoma, rhabdomyosarcoma, hapatoblastoma and especially in retinoblastoma. Since bone marrow is the likely source for circulating Fc, its Fc-immunohistochemical evaluation could be an early sign for the onset of those diseases, as for example in childhood leukaemia where HbF has already been proved as a prognostic marker (Rautonen and Siimes, 1990). In those cases the examination of bone marrow is advantageous over other tissue examinations, because sampling bone marrow aspirates is easier than collecting biopsies or resected specimens. In our introduction, we noted the possible association between the HbF gene reactivation and DNhpom implicated in oncogenesis. A support for this association is found in the recent literature noting the importance of DNhpom in embryonic tumours, found here to contain high concentration of F-cells, including nephroblastoma (Mares et al, 2001) and neuroblastoma (Banelli et al, 2005). However, DNhpom is not always involved in the mechanisms of reactivation HbF gene re-expression in cancer. There are yet other hypothetical pathways not involving DNhpom. For example the involvement of hydroxyurea – an important drug for inducing HbF biosynthesis (Atweh et al, 2003), which like DNA demethylation agents may promotes carcinogenesis (De Benedittis et al, 2004).

Another aspect of the abundance of F-cells inside these tumours is related to their embryonic characteristics. Some of these tumours mimic normal embryonic development, such as three-phase nephroblastoma, containing mesenchyme, tubular and glomerular elements, or neuroblastoma cells, which may differentiate to ganglion cells or neural cells. It is therefore possible that these tumours are programmed for autonomous foetal haematopoiesis by F-cell precursors. This hypothesis is supported by the finding of HbF erythroblasts (Feb), some of them in mitosis, in all of these embryonic tumours, most prominently in retinoblastoma and nephroblastoma. Another support for Fc development in tumour tissue comes from the finding of Fc, including Feb, in proliferating blood vessels. These Fc were found only in the tumour and not in other adjacent tissues like normal kidney tissue adjacent to nephroblastoma (Table 1), or brain tissue adjacent to glioblastoma, and neuroblastoma (Table 2, number 6; Figure 3A).

It seems thus that local regeneration rather than transportation through the general circulation is the source of Fc among tumour cells, and in proliferating blood vessels inside the tumours.

Top

References

  1. Atweh GF, Desimone J, Saunthararajha Y, Fathallah H, Weinberg RS, Nagel RL, Farby ME, Adams RJ (2003) Hemoglobinopathies. Hematology (Am Soc Hematol Educ Program) 14–39
  2. Banelli B, Di Vinci A, Gelvi I, Cascimo I, Allemani G, Bonassi S, Romani M (2005) DNA methylation in neuroblastic tumors. Cancer Lett 228: 37–41 | Article | PubMed | ISI | ChemPort |
  3. Brothman AR, Swanson G, Maxwell TM, Cui J, Murphy KJ, Herrick J, Speights VO, Isaac J, Rohr LR (2005) Global hypomethylation is common in prostate cancer cells: a quantitative predictor for clinical outcome? Cancer Genet Cytogenet 156: 31–36 | Article | PubMed | ISI | ChemPort |
  4. Carr BI, Rahar S, Doroshow JH, Blayney D, Goldberg D, Leong L, Asmeron Y (1987) Fetal hemoglobin gene activation in phase II study of 5,6-dihydro-5-azacydine for bronchogenic carcinoma. Cancer Res 47: 4199–4201 | PubMed | ISI | ChemPort |
  5. Choi JW, Kim Y, Fujino M, Ito M (2002) F blast production correlates strongly with upregulation of inducible nitric oxide synthase in myelodysplastic syndromes. Ann Hematol 81: 548–550 | PubMed | ISI | ChemPort |
  6. Cope JU, Tsokos M, Miller RW (2001) Ewing sarcoma and sinonasal neuroectodermal tumors as second malignant tumors after retinoblastoma and other neoplasm. Med Pediatr Oncol 36: 290–294 | Article | PubMed | ISI | ChemPort |
  7. De Benedittis M, Petruzzi M, Giardina C, Lo Muzio L, Pavia G, Serpico R (2004) Oral squamous cell carcinoma during long-term treatment with hydroxyurea. Clin Exp Dermatol 29: 605–607 | Article | PubMed | ISI | ChemPort |
  8. Ehrlich M (2005) The controversial denouement of vertebrate DNA methylation research. Biochemistry (Mosc) 70: 568–575 | PubMed | ISI | ChemPort |
  9. Ehrlich M, Jiang G, Fiala E, Dome JS, Yu MC, Long TI, Youn B, Sohn OS, Widschwendter M, Tomlinson GE, Chintagumpala M, Champagne M, Parham D, Liang G, Malik K, Laird PW (2002) Hypomethylation and hypermethylation of DNA in Wilms tumors. Oncogenes 21: 6694–6702 | Article | ChemPort |
  10. Feinberg AP, Vogelstein B (1983) Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301: 89–92 | Article | PubMed | ISI | ChemPort |
  11. Gaudet F, Hodgson JG, Eden A, Jackson-Grusby L, Dausman J, Gray JW, Leonardt H, Jaenisch R (2003) Induction of tumors in mice by genomic hypomethylation. Science 300: 489–492 | Article | PubMed | ISI | ChemPort |
  12. Itano O, Ueda M, Kikuchi K, Hashimoto O, Hayatsu S, Kawaguchi M, Seki H, Aiura K, Kitajima M (2002) Correlation of postoperative recurrence in hepatocellular carcinoma with demethylation of repetitive sequences. Oncogene 21: 789–797 | Article | PubMed | ISI | ChemPort |
  13. King-Underwood l, REnshaw J, Pittchard-Jones K (1996) Mutations in the Wilms' tumor gene WT1 in leukemias. Blood 87: 2171–2179 | PubMed | ChemPort |
  14. Lavelle DE (2004) The molecular mechanism of fetal hemoglobin reactivation. Semin Hematol 41(Suppl 6): 3–10 | Article | PubMed | ISI | ChemPort |
  15. Maiti S, Alam R, Amos C, Huff V (2000) Frequent association of beta-catenin and WT1 mutations in Wilms tumors. Cancer Res 60: 6288–6292 | PubMed | ISI | ChemPort |
  16. Mares J, Kriz V, Weinhausel A, Vodickova S, Kodet R, Hass OA, Sedlacek Z, Goetz P (2001) Methylation changes in promoter and enhancer of WT1 gene in Wilms' tumors. Cancer Lett 166: 165–171 | Article | PubMed | ISI | ChemPort |
  17. Markaki EA, Tsopanomichalou M, Dimitriou H, Stiakaki E, Perdikoyanni C, Spandidos D, Kalmanti M (2001) Mutations of retinoblastoma gene (Rb-1) as a prognostic factor in children with acute leukemia and neuroblastoma. Pediat Hematol Oncol 18: 101–110 | ISI | ChemPort |
  18. Mroczko B, Szmitkowski M, Okulczyk B (2003) Hematopoietic growth factors in colorectal cancer patients. Clin Chem Lab Med 41: 646–651 | Article | PubMed | ISI | ChemPort |
  19. Nakagawa T, Kanai Y, Ushijima S, Kitamura T, Kakizoe T, Hirohashi S (2005) DNA hypomethylation on pericentromeric satellite regions significantly correlated with loss of heterozygosity on chromosome 9 in urothelial carcinoma. J Urol 173: 243–246 | PubMed | ISI | ChemPort |
  20. Rautonen J, Siimes A (1990) Initial blood fetal hemoglobin concentration is elevated and is associated with prognosis in children with acute lymphoid or myeloid leukemia. Blut 61: 17–20 | Article | PubMed | ISI | ChemPort |
  21. Reinhardt D, Hasse D, Schoch C, Wollenweber S, Hinkelmann EV, Heyden W, Lentini G, Wormann B, Schroter W, Pekrun A (1998) Hemoglobin F in myelodispastic syndrome. Ann Hematol 76: 135–138 | Article | PubMed | ISI | ChemPort |
  22. Sanchez F, Mateu E, Beneyto M, Najera C, Prieto F (2000) A constitutional homozygous mutation in the RB1 gene in apatient with unilateral retinoblastoma. J Med Genet 37: 615–620 | Article | PubMed | ISI | ChemPort |
  23. Saunthararajah Y, Lavelle D, DeSimone J (2004) DNA hypo-methylating agents and sickle cell disease. Brit J Haematol 126: 629–636 | ISI | ChemPort |
  24. van den Berg H (2002) Biology and therapy of malignant solid tumors in childhood. In: Giacone G, Schilski R, Sondel P (eds). Cancer Chemotherapy and Biological Response Modifiers. Ann 20. Elsevier Science B.V: The Netherlands, pp 605–625
  25. Van den Eyden GG, Van Laere SJ, Vander Auwera I, Merajver SD, Van Marck EA, Van Dam P, Vermeulen PB, Dirix LY, Van Golen KL (2005) Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer. Breast Cancer Res Treat Oct 22: 1–10 | Article |
  26. Wagner N, Wagner KD, Schley G, Coupland SE, Heiman H, Grantyn R, Scholz H (2002) The Wilms' tumor suppressor Wt1 is associated with the differentiation of retinoblastoma cells. Cell Growth Differ 13: 297–305 | PubMed | ISI | ChemPort |
  27. Wolk M, Kieselstein M, Gera Ben-Dor C, Brufman G (1991) Fetal hemoglobin screening in whole blood and in plasma of cancer patients. Tumor Biol 12: 45–51 | ISI | ChemPort |
  28. Wolk M, Martin JE, Reinus C (2004) Blood cells with fetal haemoglobin (F-cells) detected by immunohistochemistry as indicators of solid tumors. J Clin Pathol 57: 740–745 | Article | PubMed | ISI | ChemPort |
  29. Wolk M, Martin JE, Reinus C (2006) Development of fetal haemoglobin-blood cells (F cells) within colorectal tumour tissues. J Clin Pathol 59: 598–602 | Article | PubMed | ISI | ChemPort |
  30. Wolk M, Newland AC, De La Salle B, Peleg M, Brufman G (1999) Refinement of plasma fetal hemoglobin (HbF) measurements, as related to whole blood HbF in cancer patients. J Tumor Marker Oncol 14: 115–124 | ISI |
  31. Wolk M, Newlands ES (2004) The correlation between fetal hemoglobin and outcome in non-Hodgkin's lymphoma. The Internat. J Biol Markers 19: 168–169 | ChemPort |
  32. Yamada Y, Jackson-Grusby L, Linhart H, Meissner A, Eden A, Lin H, Jaenisch R (2005) Opposing effects of DNA hypomethylation on intestinal and liver carcinogenesis. Proc Natl Aacad Sci USA 102: 13580–13585 | ChemPort |
  33. Yoshida M, Nosaka K, Yasunaga JI, Nishikata I, Morishita K, Matsuoka M (2004) Aberrant expression of the MELIS gene identified in association with hypomethylation in adult T-cell leukaemia cells. Blood 103: 2753–2760 | Article | PubMed | ISI | ChemPort |
Top

Acknowledgements

For their excellent methodological and technical assistance we thank C Nickols, A Brown, C Evagora from the Unit of Experimental Pathology at the Royal London Hospital and M Partyka from the Department of Histology and Embryology, Poznan University of medical Science, Poland. We thank S Heather from the laboratory of Entomology, Israel Ministry of Health. For help in preparing the manuscript. This work was supported by a travel grant to MW from the Leo Baeck (London) lodge, B'nai B'rith.

Top

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated

RESEARCH

Identification of IGFBP-6 as an effector of the tumor suppressor activity of SEMA3B

Oncogene Original Article

Interaction of heterocellular hereditary persistence of foetal haemoglobin with β thalassaemia and sickle cell anaemia

Nature Letters to Editor (18 Nov 1976)